Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Licensing Agreement with Cipher Pharmaceuticals
Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Distribution Agreement with Cipher Pharmaceuticals
New York – April 1, 2015 – Securities and Corporate law firm Sichenzia Ross Friedman Ference LLP has announced today that the Firm represented Can-Fite Biopharmaceuticals Ltd., (NYSE MKT: CANF) an Israeli biopharmaceutical company developing therapeutic products, in a multi million dollar Distribution Agreement where Cipher Pharmaceuticals, Inc. will distribute Can-Fite’s leading drug candidate, CF101 in the Canadian market for certain indications upon receipt of regulatory approval.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Greg Sichenzia and Gary Emmanuel.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Real Estate Group Represents One Wall Partners in a $63 Million, 16-Building, Portfolio Acquisition - September 20, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar & Co., LLC in $10 Million Public Offering of American Depository Shares of BiondVax Pharmaceuticals Ltd. (Israel) - September 19, 2017
- Los Angeles Times Interviews Gregory Sichenzia on Google’s Potential Investment in Lyft - September 17, 2017